靶向结合免疫激活治疗CLDN18.2阳性胃癌的研究进展  

Research progress on targeted therapy combined with immune-activating strategies in CLDN18.2-positive gastric cancer

作　　者：聂扬 汪越 魏嘉[1] NIE Yang;WANG Yue;WEI Jia(The Comprehensive Cancer Centre of Drum Tower Hospital,Medical School of Nanjing University,Nanjing 210008,Jiangsu,China)

机构地区：[1]南京大学医学院附属鼓楼医院肿瘤中心,江苏南京210008

出　　处：《中国临床药理学与治疗学》2025年第2期146-158,共13页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：国家自然科学基金青年项目(82403862);南京市卫生科技发展项目(YKK23084)。

摘　　要：紧密连接蛋白18.2(Claudin18.2,CLDN18.2)是一种参与细胞间紧密连接的重要结构蛋白,在正常组织中限制性表达,而在胃癌、胰腺癌、食管癌等恶性肿瘤中特异性高表达,成为颇具潜力的肿瘤治疗新靶点。目前CLDN18.2靶向治疗已经取得了一定进展,此外,近年来越来越多的研究表明CLDN18.2阳性胃癌可能具有独特的免疫微环境,靶向与免疫激活相结合治疗CLDN18.2阳性胃癌可能能够发挥协同治疗作用,进一步提高在晚期胃癌患者中的治疗效果。本文重点介绍并讨论了CLDN18.2阳性胃癌的免疫微环境特征,并总结了目前靶向结合免疫激活治疗CLDN18.2阳性胃癌的相关研究探索和临床试验进展。Claudin 18 isoform 2(Claudin18.2,CLDN18.2)is a crucial structural protein involved in cell-cell tight junctions.While its expression is limited in normal tissues,it is specifically overexpressed in malignant tumors such as gastric cancer,pancreatic cancer,and esophageal cancer,making it a promising therapeutic target for cancer treatment.Recent advances in CLDN18.2-targeted therapies have been encouraging,and studies suggest that CLDN18.2-positive gastric cancer may possess a unique immune microenvironment.This raises the potential for combining targeted therapies with immune activation to achieve synergistic effects,potentially improving treatment outcomes for patients with advanced gastric cancer.This review will focus on the immune microenvironment characteristics of CLDN18.2-positive gastric cancer and summarize the current research and clinical trial progress in targeted therapies combined with immune activation for this specific cancer type.

关 键 词：胃癌 Claudin18.2 肿瘤免疫微环境 靶向治疗 

分 类 号：R735.2[医药卫生—肿瘤] R730.51[医药卫生—临床医学]